Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The worldwide Cancer Immunotherapy market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 12.2% during the forecast period.
This report presents the market size and development trends by detailing the Cancer Immunotherapy market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Cancer Immunotherapy market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Cancer Immunotherapy industry and will help you to build a panoramic view of the industrial development.
Cancer Immunotherapy Market, By Type:
Melanoma
Colorectal cancer
Prostate cancer
Head and neck cancer
Breast cancer
Lung cancer
Other
Cancer Immunotherapy Market, By Application:
Hospitals
Clinics
Others
Some of the leading players are as follows:
Novartis
Viralytics Ltd
Merck
F. Hoffman La-Roche
Bristol-Myers Squibb
Bayer AG
Immunomedics
Eli Lilly and Company
Peregrine Pharmaceuticals
Amgen
Pfizer
Janssen Global Services
AstraZeneca
F Hoffman La-Roche
Geographically, Major regions are analyzed in details are as follows:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East & Africa
Table of Contents
1 Methodology and Scope
-
1.1 Market Segmentation & Scope
-
1.1.1 Technology Type
-
1.1.2 Product
-
1.1.3 Application
-
1.1.4 Regional scope
-
1.1.5 Estimates and forecast timeline
-
1.2 Research Methodology
-
1.3 Information Procurement
-
1.3.1 Purchased database
-
1.3.2 Internal database
-
1.3.3 Secondary sources
-
1.3.4 Primary research
-
1.3.5 Details of primary research
-
1.4 Information or Data Analysis
-
1.4.1 Data analysis models
-
1.5 Market Formulation & Validation
-
1.6 Model Details
-
1.6.1 Commodity flow analysis
-
1.6.2 Volume price analysis
-
1.7 List of Secondary Sources
-
1.8 List of Abbreviations
2 Executive Summary
-
2.1 Market Outlook
-
2.2 Segment Outlook
3 Market Variables, Trends, & Scope
-
3.1 Market Lineage Outlook
-
3.1.1 Parent market outlook
-
3.1.2 Ancillary market outlook
-
3.2 Market Segmentation
-
3.2.1 Analysis
-
3.3 Market Dynamics
-
3.3.1 Market driver analysis
-
3.3.2 Market restraint analysis
-
3.3.3 Industry opportunities
-
3.4 Penetration & Growth Prospect Mapping
-
3.4.1 Penetration & growth prospect mapping analysis
-
3.5 Business Environment Analysis Tools
-
3.5.1 Porter's five forces analysis
-
3.5.2 PESTLE analysis
-
3.5.3 Major deals & strategic alliances analysis
4 Cancer Immunotherapy Market: Technology Type Analysis
-
4.1 Cancer Immunotherapy Technology Type Market Share Analysis, 2018 & 2026
-
4.2 Cancer Immunotherapy Technology Type Market: Segment Dashboard
-
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment
4.3.1 Melanoma
4.3.2 Colorectal cancer
4.3.3 Prostate cancer
4.3.4 Head and neck cancer
4.3.5 Breast cancer
4.3.6 Lung cancer
4.3.7 Other
5 Cancer Immunotherapy Market: Product Analysis
-
5.1 Cancer Immunotherapy Product Market Share Analysis, 2018 & 2026
-
5.2 Cancer Immunotherapy Product Market: Segment Dashboard
-
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment
6 Cancer Immunotherapy Market: Application Analysis
-
6.1 Cancer Immunotherapy Application Market Share Analysis, 2018 & 2026
-
6.2 Cancer Immunotherapy Application Market: Segment Dashboard
-
6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment
6.3.1 Hospitals
6.3.2 Clinics
6.3.3 Others
7 Cancer Immunotherapy Market: Regional Analysis
-
7.1 Cancer Immunotherapy Regional Market Share Analysis, 2018 & 2026
-
7.2 Cancer Immunotherapy Regional Market: Segment Dashboard
-
7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)
-
7.4 List of Players at Regional Level
-
7.4.1 North America
-
7.4.2 Europe
-
7.4.3 Asia Pacific
-
7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
-
7.5.1 North America
-
7.5.2 Europe
-
7.5.3 Asia Pacific
-
7.5.4 Latin America
-
7.5.5 MEA
-
7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026
-
7.6.1 North America
-
7.6.2 Europe
-
7.6.3 Asia Pacific
-
7.6.4 Latin America
-
7.6.5 Middle East & Africa
8 Competitive Analysis
-
8.1 Recent Developments & Impact Analysis, by Key Market Participants
-
8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)
-
8.3 Vendor Landscape
-
8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)
9 Company Profiles
9.1 Novartis
9.1.1 Novartis Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.1.5 SWOT analysis
9.2 Viralytics Ltd
9.2.1 Viralytics Ltd Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.2.5 SWOT analysis
9.3 Merck
9.3.1 Merck Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.3.5 SWOT analysis
9.4 F. Hoffman La-Roche
9.4.1 F. Hoffman La-Roche Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.4.5 SWOT analysis
9.5 Bristol-Myers Squibb
9.5.1 Bristol-Myers Squibb Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.5.5 SWOT analysis
9.6 Bayer AG
9.6.1 Bayer AG Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.6.5 SWOT analysis
9.7 Immunomedics
9.7.1 Immunomedics Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.7.5 SWOT analysis
9.8 Eli Lilly and Company
9.8.1 Eli Lilly and Company Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.8.5 SWOT analysis
9.9 Peregrine Pharmaceuticals
9.9.1 Peregrine Pharmaceuticals Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.9.5 SWOT analysis
9.10 Amgen
9.10.1 Amgen Company overview
9.10.2 Financial performance
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.10.5 SWOT analysis
9.11 Pfizer
9.11.1 Pfizer Company overview
9.11.2 Financial performance
9.11.3 Product benchmarking
9.11.4 Strategic initiatives
9.11.5 SWOT analysis
9.12 Janssen Global Services
9.12.1 Janssen Global Services Company overview
9.12.2 Financial performance
9.12.3 Product benchmarking
9.12.4 Strategic initiatives
9.12.5 SWOT analysis
9.13 AstraZeneca
9.13.1 AstraZeneca Company overview
9.13.2 Financial performance
9.13.3 Product benchmarking
9.13.4 Strategic initiatives
9.13.5 SWOT analysis
9.14 F Hoffman La-Roche
9.14.1 F Hoffman La-Roche Company overview
9.14.2 Financial performance
9.14.3 Product benchmarking
9.14.4 Strategic initiatives
9.14.5 SWOT analysis
The List of Tables and Figures (Totals 84 Figures and 164 Tables)
Figure Melanoma Cancer Immunotherapy market, 2015 - 2026 (USD Million)
Figure Colorectal cancer Cancer Immunotherapy market, 2015 - 2026 (USD Million)
Figure Prostate cancer Cancer Immunotherapy market, 2015 - 2026 (USD Million)
Figure Head and neck cancer Cancer Immunotherapy market, 2015 - 2026 (USD Million)
Figure Breast cancer Cancer Immunotherapy market, 2015 - 2026 (USD Million)
Figure Lung cancer Cancer Immunotherapy market, 2015 - 2026 (USD Million)
Figure Other Cancer Immunotherapy market, 2015 - 2026 (USD Million)
Figure Hospitals market, 2015 - 2026 (USD Million)
Figure Clinics market, 2015 - 2026 (USD Million)
Figure Others market, 2015 - 2026 (USD Million)
-
Table List of players in North America
-
Table List of players in Europe
-
Table List of players in Asia Pacific
-
Table SWOT analysis
-
Table North America Cancer Immunotherapy market, by country, 2015 - 2026 (USD Million)
-
Table North America Cancer Immunotherapy market, by type, 2015 - 2026 (USD Million)
-
Table North America Cancer Immunotherapy market, by product, 2015 - 2026 (USD Million)
-
Table North America Cancer Immunotherapy market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.S. Cancer Immunotherapy market, by type, 2015 - 2026 (USD Million)
-
Table U.S. Cancer Immunotherapy market, by product, 2015 - 2026 (USD Million)
-
Table U.S. Cancer Immunotherapy market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Canada Cancer Immunotherapy market, by type, 2015 - 2026 (USD Million)
-
Table Canada Cancer Immunotherapy market, by product, 2015 - 2026 (USD Million)
-
Table Canada Cancer Immunotherapy market, by application, 2015 - 2026 (USD Million)
-
Table Europe Cancer Immunotherapy market, by country, 2015 - 2026 (USD Million)
-
Table Europe Cancer Immunotherapy market, by type, 2015 - 2026 (USD Million)
-
Table Europe Cancer Immunotherapy market, by product, 2015 - 2026 (USD Million)
-
Table Europe Cancer Immunotherapy market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.K. Cancer Immunotherapy market, by type, 2015 - 2026 (USD Million)
-
Table U.K. Cancer Immunotherapy market, by product, 2015 - 2026 (USD Million)
-
Table U.K. Cancer Immunotherapy market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Germany Cancer Immunotherapy market, by type, 2015 - 2026 (USD Million)
-
Table Germany Cancer Immunotherapy market, by product, 2015 - 2026 (USD Million)
-
Table Germany Cancer Immunotherapy market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table France Cancer Immunotherapy market, by type, 2015 - 2026 (USD Million)
-
Table France Cancer Immunotherapy market, by product, 2015 - 2026 (USD Million)
-
Table France Cancer Immunotherapy market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Italy Cancer Immunotherapy market, by type, 2015 - 2026 (USD Million)
-
Table Italy Cancer Immunotherapy market, by product, 2015 - 2026 (USD Million)
-
Table Italy Cancer Immunotherapy market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Spain Cancer Immunotherapy market, by type, 2015 - 2026 (USD Million)
-
Table Spain Cancer Immunotherapy market, by product, 2015 - 2026 (USD Million)
-
Table Spain Cancer Immunotherapy market, by application, 2015 - 2026 (USD Million)
-
Table Asia Pacific Cancer Immunotherapy market, by country, 2015 - 2026 (USD Million)
-
Table Asia Pacific Cancer Immunotherapy market, by type, 2015 - 2026 (USD Million)
-
Table Asia Pacific Cancer Immunotherapy market, by product, 2015 - 2026 (USD Million)
-
Table Asia Pacific Cancer Immunotherapy market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table China Cancer Immunotherapy market, by type, 2015 - 2026 (USD Million)
-
Table China Cancer Immunotherapy market, by product, 2015 - 2026 (USD Million)
-
Table China Cancer Immunotherapy market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Japan Cancer Immunotherapy market, by type, 2015 - 2026 (USD Million)
-
Table Japan Cancer Immunotherapy market, by product, 2015 - 2026 (USD Million)
-
Table Japan Cancer Immunotherapy market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table India Cancer Immunotherapy market, by type, 2015 - 2026 (USD Million)
-
Table India Cancer Immunotherapy market, by product, 2015 - 2026 (USD Million)
-
Table India Cancer Immunotherapy market, by application, 2015 - 2026 (USD Million)
-
Table Latin America Cancer Immunotherapy market, by country, 2015 - 2026 (USD Million)
-
Table Latin America Cancer Immunotherapy market, by type, 2015 - 2026 (USD Million)
-
Table Latin America Cancer Immunotherapy market, by product, 2015 - 2026 (USD Million)
-
Table Latin America Cancer Immunotherapy market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Brazil Cancer Immunotherapy market, by type, 2015 - 2026 (USD Million)
-
Table Brazil Cancer Immunotherapy market, by product, 2015 - 2026 (USD Million)
-
Table Brazil Cancer Immunotherapy market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Mexico Cancer Immunotherapy market, by type, 2015 - 2026 (USD Million)
-
Table Mexico Cancer Immunotherapy market, by product, 2015 - 2026 (USD Million)
-
Table Mexico Cancer Immunotherapy market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Argentina Cancer Immunotherapy market, by type, 2015 - 2026 (USD Million)
-
Table Argentina Cancer Immunotherapy market, by product, 2015 - 2026 (USD Million)
-
Table Argentina Cancer Immunotherapy market, by application, 2015 - 2026 (USD Million)
-
Table MEA Cancer Immunotherapy market, by country, 2015 - 2026 (USD Million)
-
Table MEA Cancer Immunotherapy market, by type, 2015 - 2026 (USD Million)
-
Table MEA Cancer Immunotherapy market, by product, 2015 - 2026 (USD Million)
-
Table MEA Cancer Immunotherapy market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table South Africa Cancer Immunotherapy market, by type, 2015 - 2026 (USD Million)
-
Table South Africa Cancer Immunotherapy market, by product, 2015 - 2026 (USD Million)
-
Table South Africa Cancer Immunotherapy market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Nigeria Cancer Immunotherapy market, by type, 2015 - 2026 (USD Million)
-
Table Nigeria Cancer Immunotherapy market, by product, 2015 - 2026 (USD Million)
-
Table Nigeria Cancer Immunotherapy market, by application, 2015 - 2026 (USD Million)
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Company market position analysis
Table Company Profiles
Table Novartis Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Viralytics Ltd Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Merck Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table F. Hoffman La-Roche Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Bristol-Myers Squibb Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Bayer AG Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Immunomedics Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Eli Lilly and Company Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Peregrine Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Amgen Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Pfizer Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Janssen Global Services Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table AstraZeneca Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table F Hoffman La-Roche Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
-
